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ABSTRACT 
 
 The mutations of the KRAS gene at codons 12, 13, and 61 have been widely reported with 
different prognosis. In silico is one approach to explain the characteristics of the mutant genes. This 
study aimed to reveal the potential energy and fluctuations of the binding site and active site of wild-
type KRAS (KRAS Wt) and mutant KRAS (KRAS Mt) at codons 12, 13, and 61. The samples used in 
this study were the sequences of KRAS Wt and KRAS Mt genes, which were subjected to in-silico 
analysis that included molecular homology, docking, and dynamics using MOE, PyMOL, and online 
CABS servers. The results showed that fluctuations in the binding site of all KRAS Mt were lower 
than that of KRAS Wt. On the contrary, the active site (switch I and switch II) of KRAS Mt fluctuated 
more widely than KRAS Wt. The potential energy of KRAS Mt before forming a complex with GTP 
was higher (p<0.01) than KRAS Wt. After this formation, it remained higher at codons 12 and 61 but 
lower at codons 11 and 13 (p <0.001). Mt G12A did not show any changes. The higher fluctuations in 
the switch I and switch II regions and the post energy of KRAS-GTP complexes may explain why 
types of cancers with mutations at codons 11 and 13 have a better prognosis than those with mutations 
at codons 12 and 61. 
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INTRODUCTION  
 Abnormalities in cell division are often associated with deviations of proteins involved in cell 
proliferation and differentiation, which are observable from any conformational changes in the 
geometric structure. 
The Ras Protein and its family, including KRAS, NRAS, and HRAS, are proto-oncogenes, 
which play roles in transmitting surface receptor signals to effector protein through the PIK3/AKT 
and RAF/MEK/ERK pathways. These two pathways are responsible for the process of cell 
proliferation and differentiation. KRAS, NRAS, and HRAS can turn into oncogenes due to mutations 
in one or more of their base pairs that may increase cell proliferation and differentiation activities and, 
thereby, trigger resistance to epidermal growth factor receptor (EGFR) monoclonal antibodies 
(Knickelbein  and Zhang, 2014). 
 Point mutations in the KRAS gene are a type of mutation most commonly found in cancer 
patients (Karnoub and Weinberg, 2008). The most frequently reported types of cancer that have this 
gene mutation include pancreatic cancer (up to 70-80%) (Stephen et al., 2014; Garcea et al., 2005), 
colorectal cancer (up to 40%-90%), lung cancer (30%), breasts cancer (<5%), and fewer types of 
cancer (de Roock et al., 2010; Forbes et al., 2009). Most of the KRAS gene mutations are localized at 
codons 12, 13, and 61. However, Miyakura et al. (2002) have successfully identified mutation at 
codon 22, and Hongyo et al. (1995) have reported one at codon 11. 
 Mutations at codon 12 have been reported in up to 80% of all occurrences, while mutations at 
codon 13 reach 17% and the rest occurs at other codons (Forbes et al., 2006). The KRAS gene 
mutations in pancreatic and colon cancer have been indicated at codon 12, changing the production of 
amino acid, that is, the substitution of cysteine for glycine (G12C) (Forbes et al., 2011). In patients 
with lung cancer, the mutations occur at the same codon as pancreatic and colon cancer, but the 
alterations in amino acid production involve the conversion of glycine to aspartate (G12D) (Stephen 
et al., 2014). Also, mutations have been identified at codon 13, i.e., where glycine changes to 
aspartate, and some other amino acids, and at codon 61 that influences the conversion of glycine to 
histidine. These mutations often take place in the GDP/GTP bond or called the GTPase domain. 
 The activities of the GTPase in KRAS Wt and KRAS Mt (G12C, G12D, G12R, G12V, G13D, 
Q61H and Q61H) have been examined through in vitro analysis by Hunter et al. (2015). The results of 
this analysis showed that KRAS Mt-G12C had the highest GTPase activity, i.e., 72% compared with 
KRAS Wt. Meanwhile, the GTPase activities occurring in the other mutant forms of KRAS were 
lower, namely 27.9% in KRAS Mt-G12D, 14.1% in G13D, 6.2% in G12V, 2.6% in G12R, 1.9% in 
G12A, 1.9% in Q61H, and, the lowest, 1.1% in Q12L compared with KRAS Wt. 
 The hydrolysis process can be described through the interactions between KRAS Wt and 
GTPase-activating protein (GAP) complex, specifically between the amino acids Q61 in KRAS Wt, 
as well as δ and β GTP, with the amino acid R789 in GAP. The NH2 group of the amino acid R789 in 
GAP interacts with the CO group of KRAS Wt protein with a bond distance of 2.7 Å. The connection 
between the NH group of the amino acid R789 in GAP with O (δ and β) atoms in phosphate resulted 
from hydrolyzed GTP occurs with the bond distances of 2.8 and 3.2 (Å) (Scheffzek et al., 1997). Gao 
and Leif (2013) also illustrate that the side chain position of Y32 phenol of KRAS Wt protein shifts 
away from the δ- and β-phosphate of GTP, whereas R789 in GAP is closer to the δ- and β-phosphate 
of GTP. Y32 phenol group in KRAS Wt is within the distance of 7Å to the R789 in GAP, but it is 
shorter in KRAS Mt-D31N and D33N (±4 Å). Accordingly, Y32 in KRAS Wt is assumed to play an 
essential role in opening the gate between this group and the GTP binding site. 
 According to Futatsugi and Tsuda (2001), the position and orientation of Q61 affect the ability 
to activate the water molecule 175 (W175). W175, located close to the δ-phosphate in GTP, is 
considered as a requirement for the hydrolysis process of GTP to GDP. Krengel et al. (1990) also 
confirm this claim after observing KRAS Mt-G12R or G12V mutations. Aside from W175, Lysine 16 
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has also been reported to be directly involved in the hydrolysis process of the phosphate groups of 
GTP to GDP when the distances between N atoms (Lys 16) and O1 atoms in the δ-phosphate and β-
phosphate of GTP are approximately 3 and 2 Å, respectively (Krengel et al., 1990). Mutations at 
codons 12, 13, and 61 are believed to cause changes in the orientation and distance of some of these 
amino acids. 
 The in vitro test of the activity of the KRAS-GAP complex, including KRAS Wt and KRAS Mt 
(G12C, G12D, G12R, G12V, G13D, Q61H, and Q61H), has also been carried out by Hunter et al. 
(2015). Based on the test results, the GAP-catalyzed hydrolysis of GTP becomes lower when GTP 
binds to mutated KRAS. KRAS Mt-G12D exhibited the highest catalytic activity, namely 2.07% 
activity compared with KRAS Wt. The catalytic activities of the other mutant forms of KRAS varied 
from 0.12% to 0.74% (0.74% in G12A, 0.56% in G12V, 0.46% in G12C, 0.46% in G12R, 0.46% in 
G13D, 0.28% in Q61L, and, the lowest, 0.12% in Q61H). 
 The intrinsic GTPase activity of KRAS and its sensitivity to GAP can also be predicted from 
other parameters, such as the fluctuations of residues in the GTPase and the two binding motifs in 
KRAS, namely Switch I and Switch II. Potential energy can also be used in completing the prediction 
of GTPase activity. The characteristics of these two parameters are useful in assessing the prognosis 
and healing expectancy of cancer therapy. 
  
MATERIALS AND METHOD  
Materials 
In this experiment, some programs were used to analyze the mutation of codons. PyMOL v. 
0.99 was applied for visualization, MOE 2007.09 for docking and homology modeling, and online 
CABS flex server for fast simulation of protein structure fluctuations. The data of the sequence of 
amino acids in KRAS enzyme (Homo Sapiens) was obtained from uniprot.org database (P01116). The 
KRAS protein template was downloaded from pdb.org (GDP ID: 1WQ1). 
 
Methods 
The sequences were transformed according to the mutated amino acids at codons 11, 12, 13, 
and 61 in FASTA format. The binding sites were identified using MOE, followed by creating KRAS 
Wt and KRAS Mt enzyme models (A11P, G12A, G12C, G12D, G13A, G13C, G13D, and Q61H). All 
models were evaluated structurally based on the root-mean-square deviation (RMSD) scores and plots 
of amino acid residues (Ramachandran Plots) (Petsko and Ringe, 2004). Both ligands and enzymes 
were prepared and optimized for their three-dimensional structures by adding hydrogen, removing 
water molecules, adding partial charges, and minimizing energy. Following this procedure was the 
docking process through the predetermined binding sites. The resulting enzyme-ligand complex was 
saved in .pdb format, while the docking value was in .mdb. All homology modeling and docking 
processes were carried out in MOE software. 
 
Data Analysis 
 The docking results were evaluated by visualization in MOE and PyMol software. Afterward, 
the analysis continued to the simulation of molecular dynamics for all KRAS before (pre-test) and 
after (post-test) the formation of the ligand-receptor complex. In this step, MOE was employed to 
observe potential energy changes, while the CABS-dock web server was used to identify the 
fluctuations of the constituent amino acids of KRAS Wt/Mt. These data were analyzed statistically. 
 
RESULTS AND DISCUSSION  
This research aimed to investigate the potential energy and fluctuations of the binding site and 
active site of KRAS Wt and KRAS Mt. The results showed that all types of modeled KRAS Mt had 
99% structural similarity to the KRAS Wt gene with RMSD<1 Å. Based on the Ramachandran plot 
analysis presented in Figure 1, all models are considered to have good quality.  
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    The fluctuations of the binding sites and active sites in the KRAS 
Wt and Mt models (A11P & Q61H) 
Ramachandran plots of  
the KRAS Wt/Mt models 
 
 
1. 94.17% residue in the core region 
of KRAS Wt 
2. 94.51% residue in the core region; 
RMSD= 0.55 Å (Mt A11P) 
3. 94.51% residue in the core region; 
RMSD= 0.74 Å (Mt Q61H) 
 
 
 
1. 93.90% residue in the core region; 
RMSD= 0.67 Å (Mt G12A) 
2. 93.90% residue in the core region; 
RMSD= 0.65 Å (Mt G12C) 
3. 92.07% residue in the core region; 
RMSD= 0.59 Å (Mt G12D) 
 
 
 
1. 93.90% residue in the core region;  
RMSD= 0.55 Å (Mt G13A) 
2. 92.07% residue in the core region; 
RMSD= 0.73 Å (Mt G13C) 
3. 92.68% residue in the core region;  
RMSD= 0.71 Å (Mt G13D) 
 
Figure 1. The fluctuations of the binding site and active site and the Ramachandran plots of the 
KRAS Wt/Mt models 
 
 All models in this experiment meet the requirements of a good-quality structure, namely RMSD 
is <1 Å and the Ramachandran plot shows >85% of amino acid residues in the core region and <15% 
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of non-glycine residues in the disallowed region (Petsko and Ringe, 2004). Therefore, all models were 
subjected to the subsequent analysis. 
 The KRAS models in Figure 1 show similarities to each other, and the difference mainly lies in 
the sensitive areas, such as the GTP binding site (codons 11-16), the switch I region (codons 30-38), 
and the switch II region (codons 60-68). The atomic fluctuations of the GTP binding sites in KRAS 
Mt and KRAS Wt tended to decrease, as listed in Table I. 
 
Table I. Regional fluctuations in "the Domains of the GTP Binding Sites" in KRAS Wt and Mt 
 
Amino 
Acids 
Fluctuations of "the Domains of the GTP Binding Sites" in KRAS Wt/Mt 
KRAS 
Wt 
A11P G12A G12C G12D G13A G13C G13D Q61H 
11 2.2829 1.5422 2.8341 2.9584 1.8792 2.7353 2.4189 2.4697 3.1452 
12 4.1773 3.4073 3.6534 3.8766 2.5942 4.3199 4.385 4.6821 4.656 
13 4.9354 4.788 4.4967 4.8156 3.2418 4.181 3.8921 4.4376 4.3667 
14 5.6709 4.9264 5.4386 4.2243 3.8444 4.9389 5.0522 4.8114 4.9665 
15 1.8831 1.7213 1.5381 1.6565 1.3983 1.7077 1.3699 1.7444 1.5218 
16 1.037 0.861 0.8577 0.8916 0.8445 0.7514 0.7871 0.698 0.8127 
 
 The decreased residual fluctuations in the GTP binding sites creates a more stable affinity with 
the ligands. According to Futatsugi and Tsuda (2001), the Lys 16 residue plays a crucial role in 
forming the KRAS-GTP complex. Table I shows that the fluctuations of the domains of the GTP 
binding sites in every KRAS Mt model have a downward trend. On the contrary, the changes in the 
Switch I region of KRAS Mt are more significant than KRAS Wt. The fluctuations of amino acid 
residues in Switch I have a substantial role in the affinity for and the interaction with GAP (Tyr 32). 
The data is provided in Table II. 
 
Table II. The fluctuations in the Switch I regions of KRAS Wt and Mt 
 
Amino 
Acids 
Fluctuations in the Switch I regions of the KRAS Wt and Mt 
KRAS 
Wt 
A11P G12A G12C G12D G13A G13C G13D Q61H 
30 12.1551 13.892 15.6219 14.3151 15.6995 14.201 16.1357 12.6599 13.1576 
31 12.2375 15.7626 16.8981 15.1176 16.462 14.3461 16.1103 13.8735 14.0005 
32 9.658 14.3209 13.6014 12.701 13.1438 12.3517 13.2726 12.1066 13.1425 
33 8.5287 11.5732 10.6984 9.7298 10.6493 10.5067 11.0009 10.5711 10.2635 
34 6.4181 8.4908 7.8231 7.3217 7.9124 8.2801 8.5336 7.8454 8.1675 
35 5.2895 6.3533 5.9763 5.5308 6.1249 6.1802 6.7285 6.1402 5.8718 
36 2.726 2.8175 3.0562 3.2252 3.0281 2.8167 3.3429 2.758 2.7221 
 
   Table II presents significant fluctuations of Tyr 32 in all KRAS Mt. These fluctuations are 
assumed to reduce the open conformation of Tyr 32, which allows the insertion of Arginine 789 
(amino acid; GAP) and its interactions with δ and β-phosphate (GTP) (Gao and Leif, 2013). 
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Table III shows that the fluctuations of all amino acid residues in Switch II of KRAS Mt are 
more significant than KRAS Wt, except for 61 amino acid residues. Variations in these 61 residues in 
all models (KRAS Wt and Mt) are similar, except for KRAS Mt-G12A and Q61H. Q61H fluctuates 
almost two times higher than KRAS Wt, which lowers its affinity for and its stable interaction with 
GAP (Scheffzek et al., 1997). It also reduces the ability of KRAS Mt-Q61H to activate the water 
molecule 175 that plays a major role in the hydrolysis process of δ-phosphate (GTP) (Krengel et al., 
1990). The low interaction between KRAS Mt-Q61H and GAP decreases the catalytic activity of 
GAP in hydrolyzing GTP (1.9%) (Hunter et al., 2015). 
Table III. The fluctuations in the Switch II regions of KRAS Wt and Mt 
 
 The differences in KRAS structures also affect the variations of the ligand-receptor affinity, as 
observed from the docking scores and the molecular dynamics simulations. The higher the docking 
score (more negative), the stronger the affinity for GTP (Hardono et al., 2013). Referring to the 
docking score, KRAS Wt has a relatively weaker affinity compared with KRAS Mt, except for G13C 
mutant. The ligand-receptor complex formed between GTP and KRAS Mt is stronger, and the 
signaling function of the messenger is expected to be more active than KRAS Wt. An increase in 
signaling function leads to uncontrolled cell growth and proliferation. KRAS gene mutation has been 
reported in almost 30% of cancer cases (Karnoub and Weinberg, 2008). It has also been detected in 
70-80% of pancreatic cancers, 40% of colon cancers, and up to 30% of lung cancers (Stephen et al., 
2014; Garcea et al., 2005; De Roock et al., 2010; Forbes et al., 2009). KRAS gene mutation is 
associated with improved signaling function of the messenger. 
  
 
Amino 
Acids 
Fluctuations in the Switch II regions of KRAS Wt/Mt  
KRAS 
Wt 
A11P G12A G12C G12D G13A G13C G13D Q61H 
60 3.1001 2.1412 2.8756 2.7751 2.3354 2.7159 2.7091 2.7396 2.8013 
61 5.2921 4.8806 6.0095 5.2461 4.9861 5.2799 5.2685 5.2171 7.0176 
62 8.6949 8.6693 9.0876 8.8353 9.4906 9.1431 9.4787 9.0909 10.1298 
63 5.7339 6.891 7.9939 7.8079 8.0632 7.3113 8.6477 7.474 9.9372 
64 4.3601 5.9804 5.3523 6.0744 7.2535 6.5767 7.5552 6.4304 6.2479 
65 3.0765 5.5553 5.3967 7.061 6.8789 6.1331 9.2252 6.6991 5.1462 
66 2.4828 4.3453 4.6005 5.5429 9.9412 5.4177 11.3556 8.7076 4.3489 
67 2.1309 4.2736 3.9437 5.4087 9.5005 5.4426 10.4178 8.2599 3.9634 
68 1.6122 3.3182 3.1118 3.9449 2.7546 3.1451 3.9649 2.6634 2.8068 
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Figure 2. The results of the KRAS Wt and Mt complex with the docking score of GT 
  
Docking Score Wt ( -18.4282) Docking Score Mt A11P (-18.8420) 
  
Docking Score Mt Q61H ( -19.6473) Docking Score Mt G12A (-18.5563) 
  
Docking Score Mt G12C (-20.5230) Docking Score Mt G12D (-19.6613) 
  
Docking Score Mt G13A (-20.1768) Docking Score Mt G13C (-18.1595) 
 
Docking Score Mt G13D (-18.9991) 
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 Figure 2 compares the docking results at a specified time interval (0-200 pc) based on the 
molecular dynamics simulations. Observations were conducted to investigate the potential energy 
KRAS Mt and Wt before and after the formation of KRAS-GTP complex. The potential energy of 
KRAS Mt before forming a complex with GTP was significantly higher than KRAS Wt (p <0.001), 
except for KRAS Mt-G12D and Q61H that had lower potential energy than KRAS Wt. Further 
analysis with the Tukey’s test revealed a very significant difference (p<0.001) in KRAS Mt-A11P, 
G12A, G12C, G12D, and Q61H; in contrast, KRAS Mt-G13A and G13C showed no difference 
(Table IV). 
 
Table IV. The results of One-way ANOVA of KRAS Wt and all forms of KRAS Mt 
 
Variables Means 95% CI P. Value P. Value of the Tukey’s 
Test 
KRAS Wt 389.90 353.23-426.58  
 
 
 
< 0.001 
 
Mt A11P 496.42 458.95-533.88 0.000 
Mt G12A 552.30 515.58-589.03 0.000 
Mt G12C 501.03 461.35-540.72 0.000 
Mt G12D 298.59 260.56-336.63 0.001 
MtG13A 436.01 397.11-474.90 0.088 
Mt G13C 424.53 389.15-459.92 0.200 
Mt G13D 520.01 483.07-556.95 0.000 
Mt Q61H 242.31 203.06-281.55 0.000 
 
The potential energy of the proteins after forming a complex with GTP also showed a very 
significant difference (p <0.001). Increased energy was identified in Mt G12C, G12D, and Q61H. 
These mutations cause instability in catalytic activity. As reported in Vatanseyer et al. (2017), G12D 
mutation leads to a shift in the Switch II and α3-helix and this conformational change causes a 
catalytic disturbance in which the SII movements anti-correlate with other regions. Conversely, 
decreased potential energy was found in KRAS Wt, Mt A11P, Mt G12A, G13A, G13C, and G13D. 
Table V shows a significant difference between the energy before and after the formation of KRAS-
GTP complex (p <0.001), except in Mt G12A (p> 0.01). The mutations in KRAS Mt-A11P, Mt 
G12A, G13A, G13C, and G13D are suspected of exhibiting similar behavior to KRAS Wt. According 
to Chen et al. (2013), KRAS mutations at codon 13 and KRAS Wt have identical behavior. Clinical 
observations on patients whose tumors have either mutant KRAS-Gly12Cys or mutant KRAS-
Gly12Val have worse progression-free survival than those with mutant KRAS proteins or wild-type 
KRAS in their tumors (Ihle et al., 2012). 
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Table V. The paired t-test results of the potential energy of KRAS Wt and all KRAS Mt models 
before and after forming a complex with GTP 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION  
Increased fluctuations in the switch I and switch II regions and the energy after the 
formation of KRAS-GTP complexes explain why cancer types with mutations at codons 11 
and 13 have a better prognosis than the ones at codons 12 and 61. 
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